Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 3,000 shares, a decrease of 55.9% from the December 31st total of 6,800 shares. Based on an average daily volume of 16,200 shares, the days-to-cover ratio is currently 0.2 days.

Adlai Nortye Stock Performance

NASDAQ:ANL traded up $0.07 during midday trading on Friday, reaching $2.13. The stock had a trading volume of 1,603 shares, compared to its average volume of 11,598. Adlai Nortye has a 1-year low of $1.85 and a 1-year high of $17.48. The firm’s fifty day simple moving average is $2.18 and its 200-day simple moving average is $2.47.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.